ScreenerHero

INSM Insmed Incorporated - Common Stock

NAS · US · Healthcare · Biotechnology · insmed.com
105.77USD-4.81%Mkt Cap: 24.27B $P/E: —

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD
BBIO
BridgeBio Pharma, Inc. - Common Stock
$13.15BUSD

Key Statistics

Company
Market Cap24.27B USD
Enterprise Value23.85B USD
Revenue (TTM)1.14B USD
Gross Profit483.49M USD
Net Income (TTM)-1.28B USD
Revenue/Share5.30 USD
Last Price105.77 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.7K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)143.42
PEG1.09
EV/EBITDA-30.00
EV/Revenue20.96
P/S21.33
P/B32.02
EPS (TTM)-4.10
EPS (Forward)0.77
52W Range
90.3913% of range212.75
52W High212.75 USD
52W Low90.39 USD
Profitability
Gross Margin79.73%
Oper. Margin-23.81%
EBITDA Margin-69.88%
Profit Margin-210.54%
ROE-172.78%
ROA-56.38%
Growth
Revenue Growth296.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-935.01M USD
CapEx (TTM)32.56M USD
FCF Margin-50.26%
FCF Yield-2.36%
Net Debt-420.59M USD
Net Debt/EBITDA0.53
Balance Sheet
Debt/Equity0.79
Current Ratio3.72
Quick Ratio3.13
Book Value/Sh3.47 USD
Cash/Share5.31 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMar 3, 2011
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)197.74 USD
Upside (mean)+87.0%
Target Range169.00 USD – 243.00 USD
169.00+87.0% to mean243.00
# Analysts23
Ownership
Shares Out.218.38M
Float216.93M
Insiders0.51%
Institutions104.98%
Short Interest
Short Ratio5.7d
Short % Float5.57%
Short % Out.4.95%
Shares Short10.80M
Short (prev mo.)10.89M
Technical
SMA 50119.82 (-11.7%)
SMA 200133.09 (-20.5%)
Beta0.82
S&P 52W Chg14.58%
Avg Vol (30d)2.07M
Avg Vol (10d)2.41M
Technical Indicators
RSI (14)38.6
MACD-2.1853
MACD Signal-0.3929
MACD Hist.-1.7924
BB Upper132.97 USD
BB Middle121.23 USD
BB Lower109.48 USD
BB Width19.37%
ATR (14)5.097 USD
Vol Ratio (20d)1.96x